Avidity Biosciences Inc (RNA) reported a Q3 2025 loss of $1.27 per share, falling short of the Wall Street consensus estimate of $-1.11. Revenue remained at $0.0 billion, aligning with analyst expectations but indicating no growth.
The company's financial results highlight ongoing challenges, as it continues to develop its pipeline of antibody oligonucleotide conjugates (AOCs) aimed at treating various diseases. Avidity is currently advancing three programs in clinical development, including Del-desiran, which is in the global Phase III HARBOR trial targeting myotonic dystrophy type 1 (DM1).
The firm will host an earnings conference call at a later date to provide further insights on its performance and future strategies. Investors may wish to review the full earnings release for additional context regarding the quarter's results and upcoming plans.
As of November 8, 2025, Avidity's market capitalization stands at $10.2 billion, with a trailing twelve-month EPS of $-3.56. Looking ahead, the company is set to report its next earnings on August 4, 2026, with an estimated EPS of $-1.33 and projected revenue of $2.4 million.